Moody's Investors Service ("Moody's") assigned Baa2 ratings to the new USD and EUR denominated senior unsecured notes offering of Becton, Dickinson and Company ("BD"). Net proceeds from the notes will be used to repay existing indebtedness and to cover associated fees and expenses. All other ratings...
A director at Becton Dickinson & Co sold after exercising options/sold 4,831 shares at 277.850USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direc...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Merck's (MRK) flagship Keytruda drug has substantially higher economic moats than the market realizes, and it has the potential to expand its profitability further. Uniform Accounting highlights that the market is missing Keytruda's economic potential, indicating equity upside. In addition to its solid portfolio of cash cow drugs, Merck's flagship biologic drug, Keytruda, has accelerated the company's earnings potential, helping grow Uniform ROA from 11% to 15%, and a forecast rise to 18%. As i...
Becton, Dickinson and Company (BDX:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 21.7x Uniform P/E. At these levels, the market is pricing in expectations for profitability to stabilize, but management may have concerns about their overall growth, margin recovery, and COVID-19 testing demand. Specifically, management may lack confidence in their ability to sustain Interventional segment revenue growth, Medical Delivery Solutions (MDS) revenue grow...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.